NCT07142837

Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors

A Study to Evaluate the Efficacy and Safety of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 153 (estimated)
• Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, open-label phase I/II study for participants with advanced solid tumors who have failed prior immune checkpoint inhibitor therapies.

Conditions

• Advanced Solid Tumor

Interventions

Type	Name	Description
DRUG	ZG005	ZG005 20mg/kg; once every 3 weeks；IV infusion
DRUG	Gecacitinib	Gecacitinib for dose escalations are set as 100mg Bid po. Gecacitinib for dose expansion will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.

Timeline

• Start date: 2025-09-01
• Primary completion: 2027-10-01
• Completion: 2027-12-01
• First posted: 2025-08-27
• Last updated: 2025-08-27

Locations

1 site across 1 country: China